Skip to content

EPS (Diluted) at other companies

Twist Bioscience Corporation logo
Twist Bioscience CorporationTWST
-$0.71-7.6%
Recursion Pharmaceuticals, Inc. logo
Recursion Pharmaceuticals, Inc.RXRX
-$0.22+56.0%
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
-$1.84-43.8%
Zymeworks logo
ZymeworksZYME
-$0.59-96.7%
Precigen logo
PrecigenPGEN
-$0.02+88.9%
ADMA Biologics logo
ADMA BiologicsADMA
$0.19+72.7%

Other financials

Income statement

See full
Revenue$8.3M+96.3%
Operating income-$57.5M+8.2%
Net income-$43.2M+5.4%

Balance sheet

See full
Cash & equivalents$102.1M-44.6%
Total debt$140.2M+107%
Total equity$938.1M-8.3%
Total assets$1.3B-2.8%

Cash flow

See full
Operating cash flow-$33.5M-190%
CapEx$3.8M-64.0%
Free cash flow-$37.4M-68.3%

Valuation

See full
Market cap$1.72B+59.2%
Enterprise value$1.76B+100.0%
P/S21.7×-25.0×

Profitability

See full
Operating margin-267.6%-120pp
Net margin-181.7%-77.9pp
FCF margin-238.9%-90.9pp

Returns & leverage

See full
Return on equity-14.7%-0.8pp
Debt / equity0.1×+0.1×
Current ratio14.1×+3.9×

Where this comes from

Reported directly by AbCellera Biologics Inc. in its filing.

Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.

The official record: AbCellera Biologics Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about AbCellera Biologics Inc.'s eps (diluted).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is AbCellera Biologics Inc.'s EPS (diluted)?
AbCellera Biologics Inc. (ABCL) reported EPS (diluted) of -$0.14 in Q1 2026.
How has AbCellera Biologics Inc.'s EPS (diluted) changed year-over-year?
AbCellera Biologics Inc.'s EPS (diluted) increased by 6.7% year-over-year, from -$0.15 to -$0.14.
What is the long-term trend for AbCellera Biologics Inc.'s EPS (diluted)?
Over 3 years (2021 to 2025), AbCellera Biologics Inc.'s EPS (diluted) has grown at a 1.4% compound annual growth rate (CAGR), from $0.47 to -$0.49.
What does EPS (diluted) mean?
Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.